VVT Med Receives Order from Major US Healthcare Network NorthWell Health and Enters Into Investor Relations Agreements

Executive Summary

• VVT Med received an initial order for its ScleroSafe™ varicose vein treatment system from Northwell Health, a major U.S. healthcare network.
• The company entered into investor‑relations agreements with I3 Capital Group (including a grant of 400,000 stock options and $55,000 cash compensation) and a marketing services agreement with Revolution Small Cap Marketing for CAD $40,000.
• Both agreements are subject to TSX Venture Exchange approval and shareholder ratification of the equity incentive plan.

Key Details

• Northwell Health Order
• Initial order for “several units” of ScleroSafe™ technology.
• Deployment overseen by Dr. Antonios Gasparis, Director of the Center for Vein Care at Northwell.

• Intended as a reference case to potentially expand use across Northwell’s 28 hospitals and 1,000+ clinics.

• I3 Capital Group Investor Relations Agreement

• Effective date: October 28 2025; initial term three months, auto‑renews quarterly unless 30‑day notice given.
• Compensation: $10,000 cash + HST upon signing; $10,000 + HST per month for first three months (paid end of month 3); thereafter $5,000 + HST per month for next three months, then no cash fees for six months.
• Equity component: Grant of 400,000 stock options under VVT’s equity incentive plan; two‑year term; vesting in four equal tranches of 100,000 options each, beginning three months after grant date and every three months thereafter.

• I3 currently holds or controls ~318,000 common shares plus securities to acquire an additional 57,590 shares.

• Revolution Small Cap Marketing Agreement

• Term: 90 days starting October 28 2025; renewable by mutual consent.
• Services: Social‑media marketing across X (Twitter), Facebook, YouTube, Reddit.

• Compensation: CAD $40,000 plus applicable taxes; no securities issued as payment.

• Regulatory & Shareholder Approvals

• Both agreements and the stock option grant require TSX Venture Exchange approval and shareholder ratification of the equity incentive plan.

Notable Quotes

“Only 2% of symptomatic varicose vein patients undergo treatment, largely due to the lack of ideal solutions… VVT's ScleroSafe™ enables these treatments to be completed in a more accessible manner, minimizing pain and post‑procedure care,” – Erez Tetro, CEO, VVT Med.